Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study Of Revumenib As Monotherapy Or In Combination With Jak Inhibitors In Patients With Myelofibrosis

NCT07734077 is registered in ClinicalTrials.gov with John Mascarenhas as lead sponsor.

NCT NCT07734077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07734077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study Of Revumenib As Monotherapy Or In Combination With Jak Inhibitors In Patients With Myelofibrosis
Lead sponsor
John Mascarenhas
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 1, 2028
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis